JP2014512369A5 - - Google Patents

Download PDF

Info

Publication number
JP2014512369A5
JP2014512369A5 JP2014505179A JP2014505179A JP2014512369A5 JP 2014512369 A5 JP2014512369 A5 JP 2014512369A5 JP 2014505179 A JP2014505179 A JP 2014505179A JP 2014505179 A JP2014505179 A JP 2014505179A JP 2014512369 A5 JP2014512369 A5 JP 2014512369A5
Authority
JP
Japan
Prior art keywords
seq
gdnf variant
human gdnf
human
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014505179A
Other languages
English (en)
Japanese (ja)
Other versions
JP6093345B2 (ja
JP2014512369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/031927 external-priority patent/WO2012141936A1/en
Publication of JP2014512369A publication Critical patent/JP2014512369A/ja
Publication of JP2014512369A5 publication Critical patent/JP2014512369A5/ja
Application granted granted Critical
Publication of JP6093345B2 publication Critical patent/JP6093345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014505179A 2011-04-11 2012-04-03 ヒトgdnfの変異体 Active JP6093345B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
US61/474,024 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (3)

Publication Number Publication Date
JP2014512369A JP2014512369A (ja) 2014-05-22
JP2014512369A5 true JP2014512369A5 (enExample) 2015-04-23
JP6093345B2 JP6093345B2 (ja) 2017-03-08

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505179A Active JP6093345B2 (ja) 2011-04-11 2012-04-03 ヒトgdnfの変異体

Country Status (28)

Country Link
US (1) US9243046B2 (enExample)
EP (1) EP2696889B1 (enExample)
JP (1) JP6093345B2 (enExample)
KR (1) KR101554799B1 (enExample)
CN (1) CN103635201B (enExample)
AU (1) AU2012243178B2 (enExample)
BR (1) BR112013026004B1 (enExample)
CA (1) CA2833158C (enExample)
CY (1) CY1119750T1 (enExample)
DK (1) DK2696889T3 (enExample)
EA (1) EA025129B1 (enExample)
ES (1) ES2656020T3 (enExample)
HR (1) HRP20171993T1 (enExample)
HU (1) HUE036239T2 (enExample)
IL (1) IL228102A (enExample)
LT (1) LT2696889T (enExample)
ME (1) ME02849B (enExample)
MX (1) MX337206B (enExample)
NO (1) NO2696889T3 (enExample)
PL (1) PL2696889T3 (enExample)
PT (1) PT2696889T (enExample)
RS (1) RS56639B1 (enExample)
SG (1) SG193483A1 (enExample)
SI (1) SI2696889T1 (enExample)
TW (1) TWI583698B (enExample)
UA (1) UA112981C2 (enExample)
WO (1) WO2012141936A1 (enExample)
ZA (1) ZA201306556B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017263174A1 (en) 2016-05-13 2018-12-13 Instituto de Medicina Molecular João Lobo Antunes Methods of treating diseases associated with ILC3 cells
WO2021119827A1 (en) * 2019-12-19 2021-06-24 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー.アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳-脂肪回路を介してilc2および肥満度を制御する神経-間葉単位

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE275197T1 (de) 1991-09-20 2004-09-15 Amgen Inc Glial neurotrophe faktor
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) * 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
AU2010211438B2 (en) * 2009-02-06 2016-04-14 Academisch Ziekenhuis Maastricht Truncated cystine-knot proteins

Similar Documents

Publication Publication Date Title
IL262976A (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
WO2009033782A3 (en) Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
WO2009046824A3 (en) Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
WO2009039992A3 (en) Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
JP2016505539A5 (enExample)
WO2009046863A3 (en) Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent
FI3482765T3 (fi) Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi
JP2014521684A5 (enExample)
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
WO2009033789A3 (en) Use of a peptide as a therapeutic agent
JP2017532343A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
WO2009033760A3 (en) Use of fibronectin fragment (196-203 ) as a therapeutic agent
WO2009033764A3 (en) Use of a peptide as a therapeutic agent
WO2009039974A3 (en) Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent
JP2011225596A5 (enExample)
WO2009033737A3 (en) Use of gluten exorphin c : as a therapeutic agent
JP2011528333A5 (enExample)
NZ599930A (en) Pharmaceutical compositions for the stimulation of stem cells.
WO2009039968A3 (en) Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection
JP2014508734A5 (enExample)
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
CN102643339A (zh) 一种glp-1类似物、制备方法及其应用
WO2009033804A3 (en) Use of gamma- endorphin as a therapeutic agent